WP1066 treatment overcame STAT3-mediated cisplatin resistance in oral squamous cell carcinoma and ovarian cancer cell lines, and doxorubicin resistance in breast cancer cell lines[141-143]. This evidence concerns the gene STAT3 and ovarian cancer.